Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA.
Pan X, Huang B, Ma Q, Ren J, Liu Y, Wang C, Zhang D, Fu J, Ran L, Yu T, Li H, Wang X, Yang F, Liang C, Zhang Y, Wang S, Ren J, Li W, Wang Y, Xiao B. Pan X, et al. Among authors: wang x, wang y, wang c, wang s. Clin Transl Med. 2022 Jul;12(7):e994. doi: 10.1002/ctm2.994. Clin Transl Med. 2022. PMID: 35876041 Free PMC article.
CircARID1A binds to IGF2BP3 in gastric cancer and promotes cancer proliferation by forming a circARID1A-IGF2BP3-SLC7A5 RNA-protein ternary complex.
Ma Q, Yang F, Huang B, Pan X, Li W, Yu T, Wang X, Ran L, Qian K, Li H, Li H, Liu Y, Liang C, Ren J, Zhang Y, Wang S, Xiao B. Ma Q, et al. Among authors: wang x, wang s. J Exp Clin Cancer Res. 2022 Aug 19;41(1):251. doi: 10.1186/s13046-022-02466-3. J Exp Clin Cancer Res. 2022. PMID: 35986300 Free PMC article.
RNA-binding protein IGF2BP2 suppresses metastasis of clear cell renal cell carcinoma by enhancing CKB mRNA stability and expression.
Ren J, Huang B, Li W, Wang Y, Pan X, Ma Q, Liu Y, Wang X, Liang C, Zhang Y, Wang S, Yang F, Li H, Ning H, Jiang Y, Qin C, Ran A, Xiao B. Ren J, et al. Among authors: wang x, wang y, wang s. Transl Oncol. 2024 Apr;42:101904. doi: 10.1016/j.tranon.2024.101904. Epub 2024 Feb 10. Transl Oncol. 2024. PMID: 38341962 Free PMC article.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: wang s. Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4. Cancer Immunol Immunother. 2024. PMID: 38727837 Clinical Trial.
109,165 results
You have reached the last available page of results. Please see the User Guide for more information.